Considering the important announcement made by the company yesterday, it may be a good idea to keep an eye on the IntelGenx Technologies Corp. (OTC:IGXT) stock this morning. The company came into focus on Monday after it announced that the first Parkinson’s disease patients had been administered Montelukast VersaFilm as part of the Phase 2 clinical trial.
The Phase 2 randomized, placebo-controlled, parallel arm, double-blind, multicenter trial would look into the efficacy of the Montekulast oral high-dose product on early to moderate Parkinson’s disease progress. In the news release, it was further noted that the study would enroll a maximum of 90 patients who would be administered 30 mg of Montelukast VersaFilm or placebo twice every day for a period of 18 months. That would be followed by a washout period of 3 months. The eligible candidates would need to be on levodopa treatment when they are enrolled and could also be on other agents of dopaminergic symptomatic nature.
The Chief Executive Officer of IntelGenx Technologies Corp., Dwight Gorham, spoke about the latest developments yesterday. He stated that the dosing of the first cohort of patients with the product in the Phase 2 trial was a major development in the clinical development pathway of Montelukast VersaFilm.
More importantly, he also revealed that the product was also being tested for treating mild to moderate Alzheimer’s disease as part of the currently ongoing BUENA Phase 2a study. He acknowledged that at this point in time, the treatment options for neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease remained limited. However, with the current studies, IntelGenx Technologies Corp. was taking major steps in providing the suffering patients with a unique disease-altering treatment with a method of dosage that could be ideal for their needs. It could be a good move to keep the stock on the watch list today.
